- Home
- GDEV vs GHRS Comparison
GDEV vs GHRS Comparison
Compare GDEV & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- GHRS
- Stock Information
- Founded
- GDEV 2009
- GHRS 2018
- Country
- GDEV Cyprus
- GHRS Ireland
- Employees
- GDEV N/A
- GHRS N/A
- Industry
- GDEV EDP Services
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- GHRS Health Care
- Exchange
- GDEV Nasdaq
- GHRS Nasdaq
- Market Cap
- GDEV 520.6M
- GHRS 470.3M
- IPO Year
- GDEV N/A
- GHRS 2021
- Fundamental
- Price
- GDEV $26.00
- GHRS $9.09
- Analyst Decision
- GDEV Buy
- GHRS Strong Buy
- Analyst Count
- GDEV 2
- GHRS 3
- Target Price
- GDEV $70.00
- GHRS $36.67
- AVG Volume (30 Days)
- GDEV 6.9K
- GHRS 65.2K
- Earning Date
- GDEV 11-14-2024
- GHRS 11-14-2024
- Dividend Yield
- GDEV N/A
- GHRS N/A
- EPS Growth
- GDEV N/A
- GHRS N/A
- EPS
- GDEV 2.48
- GHRS N/A
- Revenue
- GDEV $443,165,000.00
- GHRS N/A
- Revenue This Year
- GDEV N/A
- GHRS N/A
- Revenue Next Year
- GDEV $6.12
- GHRS N/A
- P/E Ratio
- GDEV $10.50
- GHRS N/A
- Revenue Growth
- GDEV N/A
- GHRS N/A
- 52 Week Low
- GDEV $19.00
- GHRS $5.05
- 52 Week High
- GDEV $42.76
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- GDEV 39.77
- GHRS 63.35
- Support Level
- GDEV $24.30
- GHRS $8.50
- Resistance Level
- GDEV $32.60
- GHRS $10.05
- Average True Range (ATR)
- GDEV 2.94
- GHRS 0.79
- MACD
- GDEV -1.03
- GHRS 0.10
- Stochastic Oscillator
- GDEV 9.21
- GHRS 58.55
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.